Strategic partnerships Leverage SAB BIO's ongoing collaboration with Emergent BioSolutions for process development and manufacturing of SAB-142 to position as a partner for large-scale biomanufacturing, CROs, and supply chain allies seeking robust autoimmune therapeutics production capabilities.

Clinical visibility capitalize on SAB BIO's presence at ADA Scientific Sessions and IDS Congress to generate demand for collaborations in trial design support, patient recruitment, and real-world data capture, targeting academic centers and biotech groups developing T1D or autoimmune programs.

Financial runway Align outreach with the company’s recent public financing activity and multi-year manufacturing partnerships to propose joint venture structures, milestone-driven investments, or sponsored research opportunities that reduce risk for potential strategic investors or pharma partners.

Innovative tech Position SAB BIO’s proprietary fully human antibody platform as a differentiator for pharma companies seeking next-generation immunotherapies, offering collaboration on platform licensing, joint development, or access to scalable hIgG technologies for autoimmune indications.

Global expansion Target multinational biopharma and contract manufacturing organizations that could benefit from SAB-142's disease-modifying approach in T1D by proposing cross-border clinical development programs, manufacturing SCALE-up support, and regulatory pathway alignment across regions.